Cometriq

Chemical Namecabozantinib
Dosage FormCapsules (oral; 20mg and 80mg)
Drug ClassKinase inhibitors
SystemEndocrine
CompanyExelixis, Inc.
Approval Year2012

Indication

  • For the treatment of patients with progressive, metastatic medullary thyroid cancer.
Last updated on 5/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Cometriq (cabozantinib) Prescribing Information2012Exelixis, Inc. Alameda, CA